OrbiMed Advisors LLC is a healthcare-focused investment firm founded in 1989, managing approximately $5 billion in assets. The firm specializes in a range of investment strategies, including private equity, venture capital, and public equity, targeting companies across the healthcare spectrum—from startups to large multinational corporations. OrbiMed invests in various sectors within the healthcare industry, including pharmaceuticals, biotechnology, life sciences, medical devices, and health IT. The firm typically invests between $3 million and $150 million, often seeking majority stakes in its portfolio companies. With a global investment approach, OrbiMed operates from offices in New York, San Francisco, Mumbai, Herzliya, Shanghai, West Kowloon, and Luxembourg, focusing on opportunities in North America, Europe, Asia, and Israel. Its investment strategies are underpinned by fundamental analysis, encompassing investments in public equity, fixed income, and alternative markets.
Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China.
VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity, diabetes, sleep apnea and sexual health.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions in infants. The company’s primary clinical programs include NTRA-2112, which addresses intestinal malabsorption in preterm infants by improving enteral nutrition tolerance, enhancing growth velocity, and reducing the length of stay in neonatal intensive care units. Another key product, NTRA-9620, targets short bowel syndrome by promoting bowel adaptation after surgical resection and minimizing reliance on parenteral nutrition. Nutrinia’s innovative approach includes oral formulations of insulin to support gut rehabilitation in infants. Founded in 2003 and based in Ramat-Gan, Israel, Nutrinia is dedicated to improving health outcomes for vulnerable populations.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions in infants. The company’s primary clinical programs include NTRA-2112, which addresses intestinal malabsorption in preterm infants by improving enteral nutrition tolerance, enhancing growth velocity, and reducing the length of stay in neonatal intensive care units. Another key product, NTRA-9620, targets short bowel syndrome by promoting bowel adaptation after surgical resection and minimizing reliance on parenteral nutrition. Nutrinia’s innovative approach includes oral formulations of insulin to support gut rehabilitation in infants. Founded in 2003 and based in Ramat-Gan, Israel, Nutrinia is dedicated to improving health outcomes for vulnerable populations.
Gelesis, Inc. is a biotechnology company focused on developing therapies for gastrointestinal-related chronic diseases, particularly obesity and type 2 diabetes. Utilizing a mechanobiology technology platform, Gelesis creates innovative products aimed at weight management. Its lead product, Gelesis100, is an orally administered smart pill composed of hydrogel particles that expand in the gastrointestinal tract, promoting a feeling of fullness and aiding in calorie reduction. This product is designed to be safe, having materials recognized as safe by regulatory authorities. In addition to Gelesis100, the company has a pipeline of potential therapies targeting conditions such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic idiopathic constipation. Founded in 2006, Gelesis is based in Boston, Massachusetts.